Demand for Radiotherapy in Spain

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2016 Aug 6

PMID 27492014

Citations 5

Authors

A Rodriguez

J M Borras

J Lopez-Torrecilla

M Algara

A Palacios-Eito

A Gomez-Caamano

L Olay

P C Lara

Affiliations

Soon will be listed here.

Abstract

Aim: Assessing the demand for radiotherapy in Spain based on existing evidence to estimate the human resources and equipment needed so that every person in Spain has access to high-quality radiotherapy when they need it.

Material And Methods: We used data from the European Cancer Observatory on the estimated incidence of cancer in Spain in 2012, along with the evidence-based indications for radiotherapy developed by the Australian CCORE project, to obtain an optimal radiotherapy utilisation proportion (OUP) for each tumour.

Results: About 50.5 % of new cancers in Spain require radiotherapy at least once over the course of the disease. Additional demand for these services comes from reradiation therapy and non-melanoma skin cancer. Approximately, 25-30 % of cancer patients with an indication for radiotherapy do not receive it due to factors that include access, patient preference, familiarity with the treatment among physicians, and especially resource shortages, all of which contribute to its underutilisation.

Conclusions: Radiotherapy is underused in Spain. The increasing incidence of cancer expected over the next decade and the greater frequency of reradiations necessitate the incorporation of radiotherapy demand into need-based calculations for cancer services planning.

Citing Articles

The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy.

Zhao Y, Li Y, Zhang R, Wang F, Wang T, Jiao Y Onco Targets Ther. 2020; 13:5429-5441.

PMID: 32606760 PMC: 7295539. DOI: 10.2147/OTT.S254995.

The Role of Cancer Stem Cells in Radiation Resistance.

Arnold C, Mangesius J, Skvortsova I, Ganswindt U Front Oncol. 2020; 10:164.

PMID: 32154167 PMC: 7044409. DOI: 10.3389/fonc.2020.00164.

Are there enough radiation oncologists to lead the new Spanish radiotherapy?.

Rodriguez A, Arenas M, Lara P, Lopez-Torrecilla J, Algara M, Conde A Clin Transl Oncol. 2019; 21(12):1663-1672.

PMID: 30941701 DOI: 10.1007/s12094-019-02095-x.

Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.

Gomez-Caamano A, Gonzalez-San Segundo C, Henriquez I, Maldonado X, Zapatero A Clin Transl Oncol. 2018; 21(4):420-432.

PMID: 30293231 DOI: 10.1007/s12094-018-1940-2.

Infrastructure and equipment for radiation oncology in the Spanish National Health System: analysis of external beam radiotherapy 2015-2020.

Rodriguez A, Algara M, Monge D, Lopez-Torrecilla J, Caballero F, Morera R Clin Transl Oncol. 2017; 20(3):402-410.

PMID: 28776310 DOI: 10.1007/s12094-017-1727-x.

References

Jena R, Round C, Mee T, Kirkby N, Hoskin P, Williams M . The Malthus programme--a new tool for estimating radiotherapy demand at a local level. Clin Oncol (R Coll Radiol). 2011; 24(1):1-3. DOI: 10.1016/j.clon.2011.11.009. View

Borras J, Lievens Y, Barton M, Corral J, Ferlay J, Bray F . How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiother Oncol. 2016; 119(1):5-11. DOI: 10.1016/j.radonc.2016.02.016. View

Lievens Y, Borras J, Grau C . Cost calculation: a necessary step towards widespread adoption of advanced radiotherapy technology. Acta Oncol. 2015; 54(9):1275-81. DOI: 10.3109/0284186X.2015.1066932. View

Grau C, Defourny N, Malicki J, Dunscombe P, Borras J, Coffey M . Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014; 112(2):155-64. DOI: 10.1016/j.radonc.2014.08.029. View

Popovic M, den Hartogh M, Zhang L, Poon M, Lam H, Bedard G . Review of international patterns of practice for the treatment of painful bone metastases with palliative radiotherapy from 1993 to 2013. Radiother Oncol. 2014; 111(1):11-7. DOI: 10.1016/j.radonc.2014.01.015. View

Delaney G, Jacob S, Featherstone C, Barton M . The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005; 104(6):1129-37. DOI: 10.1002/cncr.21324. View

Esco R, Palacios A, Pardo J, Biete A, Carceller J, Veiras C . Infrastructure of radiotherapy in Spain: a minimal standard of radiotherapy resources. Int J Radiat Oncol Biol Phys. 2003; 56(2):319-27. DOI: 10.1016/s0360-3016(02)04580-7. View

Slotman B, Vos P . Planning of radiotherapy capacity and productivity. Radiother Oncol. 2013; 106(2):266-70. DOI: 10.1016/j.radonc.2013.02.006. View

Barton M, Jacob S, Shafiq J, Wong K, Thompson S, Hanna T . Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol. 2014; 112(1):140-4. DOI: 10.1016/j.radonc.2014.03.024. View

10.

Tyldesley S, Boyd C, Schulze K, Walker H, Mackillop W . Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys. 2001; 49(4):973-85. DOI: 10.1016/s0360-3016(00)01401-2. View

11.

Norlund A . Costs of radiotherapy. Acta Oncol. 2003; 42(5-6):411-5. DOI: 10.1080/02841860310011140. View

12.

Borras J, Lievens Y, Grau C . The need for radiotherapy in Europe in 2020: Not only data but also a cancer plan. Acta Oncol. 2015; 54(9):1268-74. DOI: 10.3109/0284186X.2015.1062139. View

13.

Borras J, Lievens Y, Dunscombe P, Coffey M, Malicki J, Corral J . The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiother Oncol. 2015; 116(1):38-44. DOI: 10.1016/j.radonc.2015.04.018. View

14.

Lievens Y, Defourny N, Coffey M, Borras J, Dunscombe P, Slotman B . Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014; 112(2):178-86. DOI: 10.1016/j.radonc.2014.08.034. View

15.

Bentzen S, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y . Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol. 2005; 75(3):355-65. DOI: 10.1016/j.radonc.2004.12.007. View

16.

Steliarova-Foucher E, OCallaghan M, Ferlay J, Masuyer E, Rosso S, Forman D . The European Cancer Observatory: A new data resource. Eur J Cancer. 2014; 51(9):1131-43. DOI: 10.1016/j.ejca.2014.01.027. View

17.

Barton M, Allen S, Delaney G, Hudson H, Hao Z, Allison R . Patterns of retreatment by radiotherapy. Clin Oncol (R Coll Radiol). 2014; 26(10):611-8. DOI: 10.1016/j.clon.2014.03.008. View

18.

Van de Werf E, Verstraete J, Lievens Y . The cost of radiotherapy in a decade of technology evolution. Radiother Oncol. 2011; 102(1):148-53. DOI: 10.1016/j.radonc.2011.07.033. View

19.

Poortmans P, Valentini V, Lievens Y . Expanding global access to radiotherapy: the European Society for Radiotherapy and Oncology perspective. Lancet Oncol. 2015; 16(10):1148-9. DOI: 10.1016/S1470-2045(15)00288-0. View

20.

Wong K, Delaney G, Barton M . Estimation of the optimal number of radiotherapy fractions for breast cancer: A review of the evidence. Radiother Oncol. 2015; 116(2):174-8. DOI: 10.1016/j.radonc.2015.07.015. View